Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed WHO grade IV supratentorial astrocytoma (glioblastoma multiforme)~  * Newly diagnosed disease~* Has undergone maximal surgical resection~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Serum creatinine \< 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2 times ULN~* Serum bilirubin \< 1.5 mg/dL~* No known HIV infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior cranial radiotherapy~* More than 30 days since prior investigational agents~* No other concurrent investigational agents~* No concurrent use of any of the following drugs:~  * Antiarrhythmics (i.e., amiodarone or quinidine)~ * Antimycobacterials (i.e., rifampin)~ * Ergot derivatives (i.e., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)~ * Herbal products (i.e., St. John's wort)~ * HMG-CoA reductase inhibitors (i.e., lovastatin or simvastatin)~ * Neuroleptics (i.e., pimozide)~ * Sedatives and/or hypnotics (i.e., midazolam or triazolam)~* Concurrent corticosteroids allowed provided dose has been stable or decreasing for ≥ 14 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): NFV-RT-Tem

Based on this trial design, predict the completion outcome and termination type (if applicable).